Affiliations: [a] Department of Medicine and Diabetes Research Center, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA | [b] Department of Basic Research, National Institute of Geriatrics, Ministry of Health, Mexico City, Mexico
Correspondence:
[*]
Correspondence to: Roger Gutiérrez-Juárez, MD, PhD, Department of Medicine and Diabetes Research Center, Albert Einstein College of Medicine, Jack & Pearl Resnick Campus, 1300 Morris Park Avenue, Bronx, NY 10461, USA. Tel.: +1 718 409 1925; Fax: +1 718 430 8557; [email protected]
Note: [1] Current address: Department of Basic Research, National Institute of Geriatrics, Ministry of Health, Mexico City, Mexico.
Abstract: Patients with Alzheimer’s disease (AD) have a higher risk for developing insulin resistance and diabetes. Amyloid plaques, a hallmark of AD, are composed of amyloid-β (Aβ). Because the mediobasal hypothalamus controls hepatic glucose production, we examined the hypothesis that its exposure to Aβ perturbs the regulation of glucose metabolism. The infusion of Aβ25-35, but not its scrambled counterpart, into the mediobasal hypothalamus of young rats, increased circulating glucose as a consequence of enhanced hepatic glucose production during pancreatic clamp studies. These findings suggest a link between AD and alterations of glucose metabolism.
